Habuchi T. Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study. Eur Urol 2023 Mar 2:S0302-2838(23)02630-1. doi: 10.1016/j.eururo.2023.
PMID: 36870797